IDL Diagnostics AB (publ), formerly AroCell AB (publ), is a Sweden-based diagnostic Company engaged in the biotechnology and medical diagnostics industry. The Company focuses on research, development, manufacturing, and commercialization of diagnostic and medical technology products. The Company has a broad product portfolio of In Vitro Diagnostics (IVD) tests that deliver clinical information for the detection of disease with indications spanning everything from urological cancers to typhoid fever. IDL Diagnostics AB (publ) develops tests that are clinically useful and economically viable. The Company provides rapid tests, laboratory tests and platform tests that improve decision making and are non-invasive, cost effective, as well as easy to perform.

Employees

Sector

Biotechnology & Medical Research

Calendar

11-05 Earnings release - Q3 2026

More about the company

Quotes

Date	Price	Change	Volume
04/09/26	SEK 0.4020	0.00%	62,769
03/09/26	SEK 0.4020	+3.34%	439,022
02/09/26	SEK 0.3890	+0.26%	22,962
01/09/26	SEK 0.3880	-1.52%	14,602
31/08/26	SEK 0.3940	-3.67%	821,875

Delayed Quote Nasdaq Stockholm

More quotes

Quarterly revenue - Rate of surprise

Company calendar

Select your edition

All financial news and data tailored to specific country editions

NORTH AMERICA

United-States

Canada

Delayed Nasdaq Stockholm 14:39:01 04/09/2026 BST			5-day change	1st Jan Change
0.4020 ^SEK	0.00%		-1.71%	+13.88%

08-20	IDL Diagnostics AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
08-20	Calendar Thursday, August 20	FW

Market Cap	92.61M 9.7M 8.34M 7.83M 7.16M 13.37M 917M 13.47M 36.06M 468M 36.41M 35.61M 1.51B	P/E 2024	-2.12x	P/E 2025	-6.69x
Enterprise Value	69.27M 7.25M 6.24M 5.86M 5.36M 10M 686M 10.08M 26.98M 350M 27.23M 26.64M 1.13B	EV / Sales 2024	0.73x	EV / Sales 2025	1.09x
Free-Float	68.64%	Yield 2024 *	-	Yield 2025	-

Markets		Quality
Nasdaq Stockholm	IDLDX	Delayed
Deutsche Boerse AG	80R	Delayed

08-20	IDL Diagnostics AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
08-20	Calendar Thursday, August 20	FW
05-27	Calendar Thursday May 28	FW
05-19	IDL Diagnostics Appoints New CEO	MT
05-19	IDL Diagnostics appoints Gustav Sten as CEO	RE
05-19	IDL Diagnostics AB Appoints Gustav Sten as CEO, Effective May 28, 2026	CI
05-13	IDL Diagnostics Q1 net sales SEK 16.7 million	RE
05-13	IDL Diagnostics AB Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
04-13	Agneta Tufvesson Alm Declines Re-Election to the Board of IDL Diagnostics AB	CI
03-19	38 stocks hit new 52-week lows on Stockholm Stock Exchange so far today	FW
03-05	IDL Diagnostics CEO to Leave; Search for Successor Starts	MT
03-05	Anders Hultman to step down as CEO of IDL Diagnostics	RE
03-05	Anders Hultman to Step Down as CEO of IDL Diagnostics AB	CI

AroCell AB Share Price

Stocks

IDLDX

SE0003883990

Biotechnology & Medical Research

Valuation : AroCell AB

Chart: AroCell AB

Latest news : AroCell AB

Press Releases : AroCell AB

Quotes and Performance

Price Extremes

Managers and Directors : AroCell AB

Latest insider transactions

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Quarterly revenue - Rate of surprise

08-21	AroCell : IDL Diagnostics attended Diplomatic Reception hosted by the Embassy of Indonesia	PU
08-21	AroCell : Presentation of IDL Diagnostics Interim Report Q2 2026	PU
08-20	IDL Diagnostics (publ) Interim Report April 1 – June 30, 2026	AQ
08-18	AroCell : IDL Diagnostics starts partnership with Analyst Group for equity research coverage	PU
05-29	AroCell : Further strengthening partnerships in Southeast Asia	PU

1 week	-1.71%
Current month	+2.03%
1 month	+3.61%
3 months	-17.96%
6 months	+14.86%
Current year	+13.88%

1 week	0.39	0.43
1 month	0.35	0.46
Current year	0.25	0.53
1 year	0.25	0.53
3 years	0.25	0.66
5 years	0.25	2.4
10 years	0.25	8.45

Manager	Title	Age	Since
Gustav Sten CEO	Chief Executive Officer	-	27/05/2026
Ellen Dittberner DFI	Director of Finance/CFO	-	17/08/2022
Leyla Ali Dholey CTO	Chief Tech/Sci/R&D Officer	-	31/12/2024

Director	Title	Age	Since
Eva Nordström BRD	Director/Board Member	56	31/12/2019
Max Pihlqvist CHM	Chairman	39	21/05/2024
Clas Runnberg BRD	Director/Board Member	74	31/12/2022

Date	Insider	Type	Main position	Quantity	% Market Cap.
02/09/21	Michael Brobjer	Buy	Executive/Senior Manager	25,000	0.0220%
02/09/21	Alf Malmberg	Buy		20,000	0.0176%
01/09/21	Eva Nordström	Buy	Director	5,353	0.0047%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
AROCELL AB	0.00%	-1.71%	-5.19%	-28.47%	9.7M
LONZA GROUP AG	-2.41%	-2.23%	-1.28%	+15.24%	50.35B
REVOLUTION MEDICINES, INC.	-1.18%	+0.87%	+438.33%	+522.38%	45.2B
IQVIA HOLDINGS INC.	-2.78%	+0.84%	+43.39%	+19.49%	44.71B
BEONE MEDICINES AG	-0.96%	-1.30%	+13.56%	+76.70%	41.24B
CELLTRION, INC.	+0.43%	-2.20%	+14.55%	+49.08%	33.08B
ASCENDIS PHARMA A/S	-2.02%	+7.44%	-	-	17.81B
MEDPACE HOLDINGS, INC.	-0.62%	-2.47%	+21.45%	+120.98%	16.56B
EUROFINS SCIENTIFIC SE	-0.82%	+0.64%	+15.99%	+28.16%	14.82B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-2.02%	-1.93%	+76.12%	+39.93%	14B
Average	-1.23%	-0.43%	+68.55%	+93.72%	27.78B
Weighted average by Cap.	-1.47%	-0.64%	+93.80%	+127.00%

	2024	2025
Net sales	57.44M 6.01M 5.17M 4.86M 4.44M 8.29M 568M 8.36M 22.37M 290M 22.58M 22.09M 936M	53.11M 5.56M 4.78M 4.49M 4.11M 7.67M 526M 7.73M 20.68M 269M 20.88M 20.42M 865M
Net income	-42.45M -4.44M -3.82M -3.59M -3.28M -6.13M -420M -6.18M -16.53M -215M -16.69M -16.33M -691M	-12.15M -1.27M -1.09M -1.03M -940K -1.75M -120M -1.77M -4.73M -61.46M -4.78M -4.67M -198M
Net Debt	-47.78M -5M -4.3M -4.04M -3.7M -6.9M -473M -6.95M -18.61M -242M -18.79M -18.38M -778M	-23.34M -2.44M -2.1M -1.97M -1.8M -3.37M -231M -3.4M -9.09M -118M -9.18M -8.98M -380M